Bifogade filer
MagleGroup Q4 2022
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Magle Chemoswed Holding AB (publ), an established innovation led healthcare group with proven growth through risk diversification and focus on high-value revenue streams, today publishes the interim report for the fourth quarter 2022 and the full year 2022.
SOLID REVENUES WITH INCREASED RETURNS
OCTOBER – DECEMBER 2022
- Net sales amounted to 45.9 MSEK (35.9)
- EBITDA equalled 5.9 MSEK (4.4)
- Operating profit (EBIT) is 2.9 MSEK (1.3)
- Profit after tax amounted to 0.8 MSEK (1.2)
- Earnings per share SEK 0.1 (0.1) per share
JANUARY – DECEMBER 2022
- Net sales amounted to 145.7 MSEK (132.1)
- EBITDA equalled 25.5 MSEK (16.8).
- Operating profit (EBIT) is 12.5 MSEK (5.2)
- Profit after tax amounted to 9.4 MSEK (4.2)
- Earnings per share SEK 0.9 (0.4) per share
Justin Pierce, CEO of Magle Chemoswed Holding AB, commented, “Looking back at the year 2022, we can conclude that Magle Group has made significant progress in the efforts of generating steadily growing revenues and profit based on its DSM (Degradable Starch Microsphere) material science platform and state-of-the-art CDMO business.”
EVENTS DURING THE REPORTING PERIOD
- AXXO Woundgel launched in Kuwait
- EmboCept® S registered in Argentina
- SmartPAN® ViP study completed
EVENTS AFTER THE REPORTING PERIOD
- Investment to expand CDMO fill and finish production capabilities has commenced in Q1, 2023
The full report can be downloaded at https://maglegroup.com/financial-reports/